
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc. has successfully closed a $57.5 million public offering, which enhances its financial position and extends its funding runway for ongoing development programs. The company's focus on innovative antibody solutions, specifically its candidates ADG20 and VYD222, is strategically aligned with addressing the evolving challenges posed by viral diseases, particularly COVID-19. Additionally, rolling forward valuation metrics from the end of 2025 to 2026 has led to a positive adjustment in projected value, indicating a promising outlook for the company's financial performance moving forward.
Bears say
Invivyd has recently experienced a significant reduction in expectations related to its market share for PEMGARDA within the immunocompromised patient segment, which suggests potential challenges in capturing market demand. Additionally, a capital raise has led to increased dilution, further exacerbating concerns about the company’s financial position, as reflected in a lowered price target from $3.00 to $1.00. Such developments indicate heightened risk factors for investors, casting a negative outlook on Invivyd's stock performance moving forward.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares